^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Avetux (rituximab biosimilar)

Associations
Trials
Company:
Avesthagen
Drug class:
CD20 inhibitor
Related drugs:
Associations
Trials
over1year
Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Translational analyses of the AVETUXIRI phase II trial (ESMO 2023)
Table: 2237P Conclusions Independently of RAS mutation, existing adaptive immune response within metastases is associated with treatment benefit. ctDNA decrease is associated with tumor response.
P2 data • PD(L)-1 Biomarker • IO biomarker • Metastases
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • RAS (Rat Sarcoma Virus)
|
RAS mutation • RAS wild-type
|
OncoSELECT
|
Erbitux (cetuximab) • Bavencio (avelumab) • irinotecan • Avetux (rituximab biosimilar)
over1year
Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study (ESMO 2023)
Conclusions Despite good tolerability, AVETUXIRI trial did not reach its efficacy endpoint. IS could be a predictive biomarker for selecting patients with potential treatment benefits.
P2 data • PD(L)-1 Biomarker • Metastases
|
CD8 (cluster of differentiation 8) • RAS (Rat Sarcoma Virus)
|
RAS mutation • RAS wild-type
|
Erbitux (cetuximab) • Bavencio (avelumab) • irinotecan • Avetux (rituximab biosimilar)
almost2years
Translational analysis and final efficacy of the AVETUX trial - Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer. (PubMed, Front Oncol)
In summary, we report the final overall survival of the AVETUX trial and propose T cell clonality and diversity as a potential marker to predict response to chemo-immunotherapy combinations in MSS mCRC by performing a central radiological review. ClinicalTrials.gov, identifier (NCT03174405).
Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker • Metastases
|
BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
|
MSI-H/dMMR • BRAF wild-type
|
Erbitux (cetuximab) • 5-fluorouracil • Bavencio (avelumab) • leucovorin calcium • Avetux (rituximab biosimilar)
over2years
Selection of PD-L1 escape variants in microsatellite stable metastatic colorectal cancer on avelumab treatment (ESMO 2022)
The patient received 4 cycles of FOLFIRI/cetuximab, followed by 4 cycles FOLFIRI/cetuximab + avelumab, followed by avelumab maintenance treatment for 10 weeks until end of treatment (EOT) due to progression in week 19...Together with the emergence of truncated PD-L1 variants, regulation of PD-L1 availabilty but not epitope disruption appears to be the key mechanistic principle towards PD-L1 escape. Future trials confirming this principle in other entities are warranted especially in patient subpopulations with rs396991.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 mutation
|
Erbitux (cetuximab) • 5-fluorouracil • Bavencio (avelumab) • irinotecan • leucovorin calcium • Avetux (rituximab biosimilar)
almost5years
Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216). (ASCO-GI 2020)
The AVETUX regimen was feasible producing a high rate of responses in MSS pts mainly occurring within the first 8 weeks. The noted ORR/ETS of 79.5% warrants further evaluation in a randomized trial. Clinical trial information: NCT03174405.
Clinical • P2 data • Combination therapy • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
|
PD-L1 expression
|
Erbitux (cetuximab) • Bavencio (avelumab) • Avetux (rituximab biosimilar)
almost5years
Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216). (ASCO-GI 2020)
The AVETUX regimen was feasible producing a high rate of responses in MSS pts mainly occurring within the first 8 weeks. The noted ORR/ETS of 79.5% warrants further evaluation in a randomized trial. Clinical trial information: NCT03174405.
Clinical • P2 data • Combination therapy • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
|
PD-L1 expression
|
Erbitux (cetuximab) • Bavencio (avelumab) • Avetux (rituximab biosimilar)